Iovance Biotherapeutics (IOVA) Common Equity (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Common Equity of $721.8 million for Q1 2026, down 6.01% year-over-year from $767.9 million in Q1 2025, and up 3.32% quarter-over-quarter from $698.6 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Common Equity (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Common Equity for 17 consecutive years, with $721.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 6.01% year-over-year to $721.8 million; the TTM figure through Mar 2026 stood at $721.8 million (down 6.01% YoY), while the FY2025 annual figure was $698.6 million, down 1.66% from the prior year.
- Common Equity climbed to $721.8 million in Q1 2026 per IOVA's latest filing, from $698.6 million in the prior quarter.
- Across five years, Common Equity topped out at $773.5 million in Q3 2024 and bottomed at $393.7 million in Q3 2022.
- Historically, Common Equity has averaged $643.7 million across 5 years, with a median of $680.0 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity slumped 43.62% — and 2023, when it soared 71.18%.
- Iovance Biotherapeutics' Common Equity stood at $499.6 million in 2022, then climbed by 17.01% to $584.6 million in 2023, then climbed by 21.52% to $710.4 million in 2024, then declined by 1.66% to $698.6 million in 2025, then gained by 3.32% to $721.8 million in 2026.
- Business Quant data shows IOVA's Common Equity at $721.8 million in Q1 2026, $698.6 million in Q4 2025, and $702.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 736.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 736.05 Mn |
| Mar 31, 2026 | 721.75 Mn |
| Dec 31, 2025 | 698.58 Mn |
| Sep 30, 2025 | 702.29 Mn |
| Jun 30, 2025 | 698.49 Mn |
| Mar 31, 2025 | 767.87 Mn |
| Dec 31, 2024 | 710.41 Mn |
| Sep 30, 2024 | 773.46 Mn |
| Jun 30, 2024 | 768.54 Mn |
| Mar 31, 2024 | 680.02 Mn |
| Dec 31, 2023 | 584.61 Mn |
| Sep 30, 2023 | 674.01 Mn |
| Jun 30, 2023 | 578.57 Mn |
| Mar 31, 2023 | 666.88 Mn |
| Dec 31, 2022 | 499.64 Mn |
| Sep 30, 2022 | 393.74 Mn |
| Jun 30, 2022 | 472.69 Mn |
| Mar 31, 2022 | 551.99 Mn |
| Dec 31, 2021 | 621.66 Mn |
| Sep 30, 2021 | 698.33 Mn |